COTA, Boston, MA, USA.
Massachusetts General Hospital Cancer Center, Boston, MA, USA.
JNCI Cancer Spectr. 2021 Jan 4;5(1). doi: 10.1093/jncics/pkaa111. eCollection 2021 Feb.
Genomic biomarkers inform treatment in multiple myeloma (MM), making patient clinical data a potential window into MM biology. We evaluated de novo MM patients for associations between specific MM cytogenetic patterns and prior cancer history. Analyzing a MM real-world dataset, we identified a cohort of 1769 patients with fluorescent in situ hybridization cytogenetic testing at diagnosis. Of the patients, 241 (0.14) had histories of prior cancer(s). Amplification of the long arm of chromosome 1 [amp(1q)] varied by prior cancer history (0.31 with prior cancer vs 0.24 without; 2-sided = .02). No other MM translocations, amplifications, or deletions were associated with prior cancers. Amp(1q) and cancer history remained strongly associated in a logistic regression adjusting for patient demographic and disease attributes. The results merit follow-up regarding carcinogenic treatment effects and screening strategies for second malignancies. Broadly, the findings suggest that analyses of patient-level phenotypic-genomic real-world dataset may accelerate cancer research through hypothesis-generating studies.
基因组生物标志物为多发性骨髓瘤 (MM) 的治疗提供了信息，使患者的临床数据成为了解 MM 生物学的潜在窗口。我们评估了初诊 MM 患者特定 MM 细胞遗传学模式与既往癌症史之间的关联。通过对 MM 的真实世界数据集进行分析，我们确定了一个 1769 名患者的队列，他们在诊断时接受了荧光原位杂交细胞遗传学检测。在这些患者中，241 名（0.14）有既往癌症史。染色体 1 长臂扩增 [amp(1q)] 因既往癌症史而异（有既往癌症 vs 无既往癌症，分别为 0.31 和 0.24；双侧 = .02）。其他 MM 易位、扩增或缺失与既往癌症无关。在调整了患者人口统计学和疾病特征后，amp(1q) 和癌症史在逻辑回归中仍然强烈相关。这些结果值得关注致癌治疗效果和第二恶性肿瘤的筛查策略。总体而言，这些发现表明，对患者水平表型-基因组真实世界数据集的分析可能通过产生假说的研究加速癌症研究。
